Female‐Versus‐Male Alloreactivity as a Model for Minor Histocompatibility Antigens in Hematopoietic Stem Cell Transplantation

H‐Y encoded gene products were the first to be recognized as clinically relevant minor histocompatibility antigens. Compared to other gender combinations, female donor/male recipient (FDMR) transplants are associated with increased graft‐versus‐host disease (GvHD), increased transplant‐related mortality (TRM) and reduced risk of relapse. Still, their relative impact on transplant outcome remains controversial. We analyzed donor/recipient sex combination in 53 988 patients treated with allogeneic hematopoietic stem cell transplantation (HSCT) between 1980 and 2005. We found a strong increase in chronic GvHD and late TRM and decreased survival in FDMR transplants irrespective of underlying disease. Conversely, FDMR patients had lower relapse rates. The negative effect on survival decreased with advancing disease stage as relapse protection became more important. Effects of H‐Y alloreactivity were most pronounced in patients transplanted from HLA‐matched donors and in those receiving transplants from an adult donor. Adjustment for acute and chronic GvHD only partially corrected the effects of H‐Y alloreactivity. Analysis of the FDMR proportion over time indicated that the frequency of this gender combination has declined in unrelated transplants over the last 10 years. These data define the role of H‐Y mismatching in allogeneic HSCT and support the current practice of avoiding female donors for male patients, if possible.

[1]  G. Gahrton Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. , 2007, Best practice & research. Clinical haematology.

[2]  J. Falkenburg,et al.  Minor histocompatibility antigen DDX3Y induces HLA-DQ5-restricted T cell responses with limited TCR-Vbeta usage both in vivo and in vitro. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  A. Gratwohl,et al.  Influence of Donor/Recipient Sex Matching on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia , 2006, Transplantation.

[4]  N. Kröger,et al.  The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants , 2005, Bone Marrow Transplantation.

[5]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[6]  E. Warren,et al.  A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene1 , 2004, The Journal of Immunology.

[7]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[8]  J. Falkenburg,et al.  Minor histocompatibility antigens in human stem cell transplantation. , 2003, Experimental hematology.

[9]  J. Drijfhout,et al.  The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. , 2002, Blood.

[10]  H. V. van Houwelingen,et al.  Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. , 2001, The hematology journal : the official journal of the European Haematology Association.

[11]  J. Falkenburg,et al.  UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. , 2000, Blood.

[12]  C. Disteche,et al.  The Human UTY Gene Encodes a Novel HLA-B8-Restricted H-Y Antigen1 , 2000, The Journal of Immunology.

[13]  J. Falkenburg,et al.  DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. , 2000, Blood.

[14]  J. Shabanowitz,et al.  Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. , 1999, Journal of immunology.

[15]  N. Rufer,et al.  HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. , 1998, Transplantation.

[16]  R. Hammer,et al.  Novel HY peptide antigens presented by HLA-B27. , 1997, Journal of immunology.

[17]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[18]  M. Pepe,et al.  Previous donor pregnancy as a risk factor for acute graft‐versus‐host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation , 1990, British journal of haematology.

[19]  E. Goulmy,et al.  ALLOIMMUNITY TO HUMAN H-Y , 1976, The Lancet.

[20]  R. Nelson,et al.  CYTOMEGALOVIRUS IN NON-B POST-TRANSFUSION HEPATITIS , 1974 .